甲磺酸阿帕替尼联合SOX方案三药转化治疗在一线治疗失败的晚期胃癌患者中的应用效果

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (430 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the efficacy of Apatinib Mesylate combined with Tegafur+Oxaliplatin (SOX) regimen for three-drug conversion therapy in patients with advanced gastric cancer who failed first-line therapy. Methods A total of 65 patients with advanced gastric cancer who failed first-line treatment in Maanshan People’s Hospital，Anhui Province from January 2018 to April 2020 were selected as the research subjects. They were divided into control group (SOX regimen, 33 cases) and study group (Apatinib Mesylate combined with SOX regimen, 32 cases) according to random number table method. The clinical efficacy, adverse reactions and one-year survival rate of the two groups were compared. Results The objective remission rate and clinical benefit rate in the study group were significantly higher than those in the control group (P < 0.05). The total incidence of adverse reactions in the study group was significantly lower than that in the control group (P < 0.05). The one-year survival rate of the study group was significantly higher than that of the control group (P < 0.05). Conclusion Three-drug conversion therapy with Apatinib Mesylate combined with SOX regimen has a significant effect on advanced gastric cancer patients with first-line treatment failure, which significantly improves the objective remission rate and clinical benefit rate, significantly reduces adverse reactions, and further improves the one-year survival rate, which is worthy of promotion.

Key words： Gastric cancer Apatinib Mesylate SOX regimen Tegafur Oxaliplatin Adverse reactions

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DU Chengrong CAO Qisheng HUANG Zhirong CHEN Lei

Cite this article:

DU Chengrong CAO Qisheng HUANG Zhirong CHEN Lei. Application efficacy of Apatinib mesylate combined with SOX regimen for three-drug conversion therapy in patients with advanced gastric cancer who failed first-line therapy#br#[J]. 中国医药导报, 2021, 18(32): 113-116.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I32/113

[1] 闫晓红，赵亚宁，汪华，等.阿帕替尼联合奥沙利铂＋替吉奥治疗晚期胃癌效果观察[J].肿瘤研究与临床，2017，29（11）：761-764.
[2] 姚荣杰，孟曼，丁露，等.甲磺酸阿帕替尼治疗二线化疗失败后晚期胃癌的效果观察[J].肿瘤药学，2018，8（1）：53-56.
[3] 阮寒光，史芳，汪华，等.甲磺酸阿帕替尼治疗二线化疗失败后晚期胃癌疗效观察[J].广东医学，2017，38（19）：3019-3022.
[4] 马德，侯娟，陈青.改良DCF化疗方案与SOX化疗方案治疗晚期胃癌对患者生活质量的影响[J].实用癌症杂志，2017，32（11）：1828-1831.
[5] 马丽华，钱屹崟，符炜，等.伊立替康联合替吉奥与mFOLFIRI方案对晚期胃癌患者二线化疗的效果比较[J].中国医药，2019，14（1）：73-76.
[6] 叶再生，曾奕，魏晟宏，等.阿帕替尼联合奥沙利铂和替吉奥在胃癌腹膜转移转化治疗中的安全性及近期疗效观察[J].中华胃肠外科杂志，2021，24（3）：240-247.
[7] 阮寒光，王红，董俊林，等.甲磺酸阿帕替尼联合替吉奥治疗晚期胃癌的疗效及影响因素分析[J].现代医药卫生，2017，33（19）：2932-2936.
[8] 徐瑞华，姜文奇，管忠震.临床肿瘤内科学[M].北京：人民卫生出版社，2014：107-108.
[9] 郎丰平，赵毓毅，范鹏.甲磺酸阿帕替尼治疗晚期胃癌的疗效及安全性分析[J].实用癌症杂志，2017，32（6）：996-998.
[10] Ter Veer E，Mohammad NH，Lodder P，et al. The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer：a systematic review and meta-analysis [J]. Gastric Cancer，2016，19（3）：696-712.
[11] 陈红凯，马玉斌.替吉奥联合奥沙利铂治疗晚期胃癌的临床研究[J].现代药物与临床，2018，33（2）：394-398.
[12] 谢博文，臧潞，马君俊，等.奥沙利铂联合卡培他滨或联合替吉奥新辅助化疗方案在进展期胃癌治疗中的安全性和有效性[J].中华胃肠外科杂志，2021，24（2）：138-144.
[13] 殷国庆，王忠，周峰，等.替吉奥与阿帕替尼单药二线治疗晚期胃癌伴肝转移的效果对比[J].广西医学，2020， 42（4）：425-428.
[14] Nishikawa K，Yamada Y，Ishido K，et al. Impact ofprogression type on over all survival in patients with advanced gastric cancer based on randomized phase Ⅲstudy of S-1 plus oxaliplatin versus S-1 plus cisplatin [J]. Gastric Cancer，2017 20（4）：640-645.
[15] 蔡明志，王学军，刘勇，等.以替吉奥为基础联合阿帕替尼的三药方案在不可切除晚期胃癌转化治疗中的应用[J].中华胃肠外科杂志，2021，24（2）：179-184.
[16] 沈东杰，刘涛，赵恩昊，等.替吉奥联合奥沙利铂治疗进展期胃癌的疗效及对癌组织中MMP-9和VEGF表达的影响[J].实用临床医药杂志，2015，19（5）：41-43，47.
[17] 冯琳.奥沙利铂联合替吉奥治疗晚期胃癌的效果观察及护理干预研究[J].药品评价，2019，16（4）：41-43.
[18] Liu X，Li G，Long Z，et al. Phase Ⅱ trial of preoperative chemoradiation plus perioperative SOX chemotherapy in patients with locally advanced gastric cance [J]. J Surg Oncol，2018，117（4）：692-698.
[19] 李淼，晋国权，陈蓉，等.甲磺酸阿帕替尼联合SOX方案二线治疗晚期胃癌的近期疗效及安全性[J].中国中西医结合消化杂志，2018，26（9）：736-741.
[20] 杨牡丹，高峻，刘晓玲，等.甲磺酸阿帕替尼联合多西他赛二线治疗晚期胃癌的临床研究[J].中华肿瘤杂志，2020，42（7）：594-597.
[21] 郭军，王娜，刘登湘，等.甲磺酸阿帕替尼片联合替吉奥和奥沙利铂治疗晚期胃癌的效果与安全性[J].中国医药，2020，15（4）：577-579.
[22] 李学超，闵庆怀，常安.甲磺酸阿帕替尼与替吉奥治疗晚期胃癌的疗效和安全性比较[J].中国肿瘤临床与康复，2018，25（10）：1241-1243.
[23] 彭飞，代雪江.阿帕替尼与奥沙利铂及替吉奥治疗晚期胃癌的疗效观察[J].内蒙古医学杂志，2020，52（1）：74-75.
[24] 卓恩挺，王连臣，陈雪莲，等.西妥昔单抗联合铂类药物灌注治疗胃癌所致恶性腹水患者的疾病控制效果[J].疑难病杂志，2019，18（10）：1022-1025，1030.
[25] 伍小平，谭业儒，李跃华，等.阿帕替尼及替吉奥治疗晚期胃癌二线化疗失败的疗效观察[J].中国卫生标准管理，2019，10（15）：78-80.
[26] 李鹏，李成浩.晚期胃癌治疗中阿帕替尼片联合奥沙利铂注射液和替吉奥胶囊的临床疗效及安全性对比分析[J].河北医学，2017，23（11）：167-170.